Company news
Minerva Neurosciences, Inc news in 2022
Minerva Neurosciences, Inc's news releases, calls and decks from 2022, newest first.
Minerva Neurosciences Reports Third Quarter 2022 Financial Results and Business Updates
November 8, 2022
Minerva Neurosciences to Report Third Quarter 2022 Financial Results and Business Updates on November 9, 2022
November 1, 2022
Minerva Neurosciences Receives Refusal to File Letter from FDA for its New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
October 16, 2022
Minerva Neurosciences Announces Listing Transfer to Nasdaq Capital Market
September 8, 2022
Minerva Neurosciences Submits New Drug Application to FDA for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia
August 21, 2022
Minerva Neurosciences Reports Second Quarter 2022 Financial Results and Business Updates
August 8, 2022
Minerva Neurosciences Reports First Quarter 2022 Financial Results and Business Updates
May 3, 2022
Minerva Neurosciences Provides Update from Type C Meeting with FDA and Next Steps in Preparation for Submission of a New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
April 6, 2022
Minerva Neurosciences Reports Fourth Quarter 2021 Financial Results and Business Updates
February 28, 2022
Minerva Neurosciences Announces Publication of Roluperidone Phase 3 Study Results in Schizophrenia Bulletin
February 27, 2022
Calls in 2022
Decks in 2022
- Corporate Update (April 2022)
Corporate update · 17 slides · Apr 13, 2022
- Investor Presentation (January 2022)
Investor deck · 27 slides · Jan 5, 2022